Overview

A Study of Injections of LY3074828 in Healthy Participants

Status:
Completed
Trial end date:
2019-10-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab